Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: A case report

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 3, 2009, Pages 194-197

  Saito, Mari ^a   Gunji, Yuji ^a   Kashii, Yoshifumi ^a   Odaka, Jun ^a   Yamauchi, Tadahiko ^a   Kanai, Nobuyuki ^a   Momoi, Mariko Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Kaposiform hemangioendothelioma; Vascular endothelial growth factor receptor (VEGFR) 2; VEGFR 3

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; METHYLPREDNISOLONE; MONOETHANOLAMINE OLEATE; NAFAMSTAT MESILATE; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VINCRISTINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; SCLEROSING AGENT; VAC PROTOCOL;

ARTICLE; AUTOPSY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INFANT; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLEROTHERAPY; STEROID THERAPY; SYMPTOM; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR RESISTANCE; TUMOR VOLUME; VASCULAR TUMOR; BIOSYNTHESIS; DRUG RESISTANCE; HEMANGIOENDOTHELIOMA; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; SOFT TISSUE TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG RESISTANCE, NEOPLASM; GUANIDINES; HEMANGIOENDOTHELIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INTERFERON-ALPHA; MAGNETIC RESONANCE IMAGING; MALE; OLEIC ACIDS; PLATELET TRANSFUSION; PREDNISOLONE; PROGNOSIS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; SOFT TISSUE NEOPLASMS; THROMBOCYTOPENIA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VINCRISTINE;

EID: 65449165247     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181979c83     Document Type: Article

References (25)

1. Tang HF, Zhou YY, Gu WZ, et al. Clinicopathologic features of kaposiform hemangioendothelioma. Zhonghua Wai Ke Za Zhi. 2004;42:1132-1135.
2. Ming-Tsung C, Chien-Hsun C, Cheng-Hsun C, et al. Successful nonoperative therapy for kaposiform hemangioendothe-lioma involving the neck: report of 1 case. Otolaryngol Head Neck Surg. 2003;129:605-607.
3. Haisley-Royster M, Enjolras O, Frieden I, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. Pediatr Hematol Oncol. 2002;24:459-462.
4. Mac-Moune LF, To KF, Choi PC, et al. Kaposiform hemangioendothelioma: five patients with cutaneous lesion and long follow-up. Mod Pathol. 2001;14:1087-1092.
5. Arnaout MK, Pappo AS. Kaposiform hemangioendothelioma with associated Kasabach-Merritt phenomenon. J Pediatr. 1998; 133:788.
6. Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol. 1998;20:567-569.
7. Blei F, Karp N, Rofsky N, et al. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol. 1998;15:295-305.
8. Deb G, Jenkner A, De sio L, et al. A spindle cell (kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. Med Pediatr Oncol. 1997;28:358-361.
9. Vin-Christian K, McCalmont TH, Frieden IJ. Kaposiform hemangioendothelioma. Arch Dermatol. 1997;133:1573-1578.
10. Fukunaga M, Ushigome S, Ishikawa E. Kaposiform heman-gioendothelioma associated with Kasabach-Merritt syndrome. Histopathology. 1996;28:281-284.
11. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100:1377-1386.
12. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for Over DIC. Am J Hematol. 2003;74:17-22.
13. Mitsuhashi N, Furuta M, Sakurai H. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys. 1997;39:467-473.
14. + T cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:1087-1096.
15. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol. 2000;42:225-235.
16. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052-1059.
17. Inagaki H, Nonami T, Kurokawa T, et al. Effect of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection. Hepatogastroenterology. 1999;46:3223-3228.
18. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Hematol. 2001;112:851-862.
19. Miller JG, Orton CI. Long term follow-up of a case of Kasabach-Merritt syndrome successfully treated with radiotherapy and corticosteroids. Br J Plast Surg. 1992;45: 559-561.
20. Marchuk DA. Pathogenesis of hemangioma. J Clin Invest. 2001;107:665-666.
21. Zhang L, Lin X, Wang W, et al. Circulating levels of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg. 2005;116: 200-204.
22. Miller MA, Sandler AD. Elevated plasma vascular endothelial growth factor levels in 2 patients with hemangioendothelioma. J Pediatr Surg. 2005;40:e17-e19.
23. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349:427-434.
24. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or reccurent solid tumors. Ann Oncol. 2008;19: 807-813.
25. Folpe AL, Veikkola T, Voltola R, et al. Vascular endothelial growth factor receptor-3 (VEGFR-3): a maker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioen-dotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13:180-185.